Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community
- Date 2 Aug 2021
Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein.
FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.
You might also be interested in these articles
Technology
Answer the call for speakers & start-ups for CW's International Conference
None
Thu 7 Nov 2024
CW (Cambridge Wireless Ltd)
Technology
Celebrating the Cambridge Tech Week Innovation Alley Award Winners
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)
Technology
Optalysys wins the Business Weekly and Cambridge Tech Week Scale-Up Business Plan Competition
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)